See how drug companies are maximizing revenue prior to an Obama administration slamming the vault door shut.
By raising drug prices for yours in advance of patent expiration, they’re hoping that prescribers “are too busy to notice that the revamped drug may offer little value over the original version, and thus will keep patients on the new one even when the generic arrives, at lower cost.”
Vyvanse and Nuvigil are cited as prime examples of this practice.
